IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models-Reference-Cited by-同舟云学术

IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

Published:2016-12-08 Issue:23 Volume:128 Page:2683-2693
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ågerstam Helena¹,Hansen Nils¹,von Palffy Sofia¹,Sandén Carl¹,Reckzeh Kristian¹,Karlsson Christine¹,Lilljebjörn Henrik¹,Landberg Niklas¹,Askmyr Maria¹,Högberg Carl¹,Rissler Marianne¹,Porkka Kimmo²,Wadenvik Hans³,Mustjoki Satu²,Richter Johan⁴,Järås Marcus¹,Fioretos Thoas¹

Affiliation:

1. Department of Clinical Genetics, Lund University, Lund, Sweden;

2. Hematology Research Unit Helsinki, University of Helsinki and Comprehensive Cancer Center, Helsinki University Central Hospital, Helsinki, Finland;

3. Department of Internal Medicine, University of Gothenburg, Gothenburg, Sweden; and

4. Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden

Abstract

Key Points IL-1 activates signaling and promotes proliferation of primitive CML cells. IL1RAP antibodies block IL-1–induced effects and mediate cell killing in chronic and blast phase CML in vivo models.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/23/2683/1397710/blood679985.pdf

Reference39 articles.

1. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining;Rowley;Nature,1973

2. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia;Ren;Nat Rev Cancer,2005

3. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study;Ross;Blood,2013

4. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease;Rousselot;J Clin Oncol,2014

5. Do we need more drugs for chronic myeloid leukemia?;Holyoake;Immunol Rev,2015

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells;Journal of Hematology & Oncology;2024-08-14

2. Circ_0003314 Combines with the miR-26b-5p/IL1RAP Axis to Inhibit HTR-8/SVneo Cell Proliferation, Migration, Invasion and Tube Formation and Promote Apoptosis;Applied Biochemistry and Biotechnology;2024-08-14

3. IL-1 in aging and pathologies of hematopoietic stem cells;Blood;2024-07-25

4. Decoding immune-related gene-signatures in colorectal neoplasia;Frontiers in Immunology;2024-06-24

5. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05